Skip to content
etf.net

Launched · SEC filings

Invesco Biotechnology & Genome ETF

PBENYSE ArcaInvescoB

$100.86−1.64 (−1.60%)

As of Nov 2, 2026, 3:59 PM ET

B57/ 100

Rank 7 of 17 in Biotech & Genomics

B57/100Rank 7 of 17inBiotech & Genomics
Intraday session: down, 79 prints from 102.50 to 100.86. Range 100.86 to 102.86. Use the arrow keys to read each point.101.50102.0010 AM12 PM2 PM4 PM
Expense ratio
0.59%
Fund size
$442M
1Y total return
+38.9%
Yield · Last 12 months
1.30%
Holdings
33
Avg volume · 30D
23.9K sh
52W range
low $73.16high $104.24
Launched
Filings
SEC EDGAR

The ETF.net PBE Grade

B

Score 57 out of 100

Category
Biotech & Genomics⁠
Rank
7 of 17
Six-pillar profile for PBE. Scores out of 100: Cost 19, Risk 76, Mission 91, Tradability 63, Holdings 49, Durability 77. Strongest: Mission (91). Weakest: Cost (19). Leans toward Mission.

Score 57 of 100 falls in the B band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.

  • Cost

    The fund’s net expense ratio, ranked against its category.
    F19 out of 100
    Rank 14 of 17

  • Mission

    Whether the fund did what it promised, tested against its stated mandate.
    A91 out of 100
    Rank 1 of 9

  • Risk

    How the fund held up when markets fell: downside volatility, drawdowns and tail loss.
    A76 out of 100
    Rank 1 of 17

  • Tradability

    How easy the fund is to trade: daily volume, and how far its price strays from net asset value.
    B63 out of 100
    Rank 6 of 17

  • Holdings

    How concentrated the fund is, and how complete and current its disclosed holdings are.
    C49 out of 100
    Rank 11 of 17

  • Durability

    Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.
    A77 out of 100
    Rank 4 of 17

Our read on PBE

ETF.net Research

In short

BMost biotech funds own the sector by size. PBE has run a different playbook since 2005: a quant screen on momentum, quality and value that narrows the field to roughly 30 names, reshuffled every quarter.

Stated mandate

The Fund seeks to track, before fees and expenses, the results of its designated biotechnology and genome benchmark index.

Why people hold it

  • The index scores biotech and genome companies on price momentum, earnings momentum, quality, management action and value, then reconstitutes quarterly, so the roster follows the scores.pionline.com
  • Trading since 2005, one of the longest-running biotech ETFs on the tape, and it has stayed tight to the index it promises to follow.
  • About 30 holdings, so an approval or a trial readout at one company registers in the portfolio instead of being diluted across a sprawling roster.
  • Sits in the upper half of the biotech and genomics group on our review, with no structural red flags in the wrapper and a plain index mandate on file with the SEC.sec.gov

Worth knowing

  • 0.59% sits above the category median, and above plain index rivals like IBB at 0.44% and XBI at 0.35%. The screening model is what you pay the difference for.
  • Thinly traded next to the category's heavyweights, so spreads can be wider and bigger orders need more care at the point of execution.
  • A 30-stock quant portfolio can diverge sharply from the broad biotech benchmark in either direction, and it pays out only quarterly.

PBE Holdings

Holdings pillarC49 out of 100Rank 11 of 17 in Biotech & Genomics
Asset class
Stocks
Holdings
33
Top-10 weight
49%
Largest holding
NTRA6.2%

Sectors

  • Health Care100.0%
  • Financials0.0%

Geography

  • United States100.00%
The fund’s holdings, weight-ordered — page 1 of 3.
#TickerCompanyWeight %SharesMarket valueHeld by ETFs
1NTRANatera Inc6.17%63,157$27.5M239
2ILMNIllumina Inc6.15%94,523$27.4M331
3BIIBBiogen Inc5.39%96,330$24M332
4GILDGilead Sciences Inc5.31%142,946$23.7M494
5RPRXRoyalty Pharma PLC5.06%342,618$22.6M204
6AMGNAmgen Inc4.97%48,086$22.2M503
7REGNRegeneron Pharmaceuticals Inc4.68%25,513$20.9M422
8VRTXVertex Pharmaceuticals Inc4.66%38,468$20.8M429
9MRNAModerna Inc3.65%73,039$16.3M297
10HALOHalozyme Therapeutics Inc3.12%106,110$13.9M219
11VCYTVeracyte Inc3.08%263,393$13.7M143
12EXELExelixis Inc3.04%204,511$13.5M251
13QGENQiagen NV3.00%265,744$13.4M49
14UTHRUnited Therapeutics Corp2.98%22,371$13.3M270
15NVAXNovavax Inc2.88%1,228,795$12.9M71

Showing 1–15 of 33 holdings

PBE Performance

Launched Jun 23, 2005

Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.

PBE$13,894
SPY tracks large US stocks. It provides market context, rather than representing this fund’s strategy, asset class or investment benchmark.$11,199
Oct 31, 2025 to Oct 30, 2026. PBE $13,894. SPY $11,199. Use the arrow keys to read each point.$10,000$12,000$14,000Oct 2025Apr 2026Oct 2026

Oct 31, 2025 – Oct 30, 2026

Returns run to the Oct 30, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.

Trailing total return for PBE. Periods over one year show the average yearly return.
PeriodPBE
Year to date+25.9%
1 month+5.2%
3 months+14.2%
1 year+38.9%
3 yearsper year+25.0%
5 yearsper year+6.9%
10 yearsper year+11.0%

With distributions reinvested.

Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.

Annual total returns for PBE
YearReturn barPBE
2026 YTD+25.9%
2025+24.8%
2024+1.1%
2023+3.7%

PBE in the news

PBE Dividends

Adds up every distribution paid per share over the last 12 months, divided by the last completed close. Distributions are counted by ex-date. Data through Oct 30, 2026.
1.30%Last 12 months
Payout per share
$1.33Last 12 months
Last payment
$0.02 per share
Paid on
Shares bought on or after this date do not qualify for this distribution.
Frequency
Quarterly

Distribution history

2017–2026

One bar per payment. 14 payments from 2017 to 2026 YTD. Mar 17, 2017 $0.06; Jun 16, 2017 $0.22; Sep 24, 2018 $0.0021; Mar 23, 2020 $0.03; Jun 20, 2023 $0.01; Mar 18, 2024 $0.02; Jun 24, 2024 $0.0082; Mar 24, 2025 $0.03; Jun 23, 2025 $0.13; Sep 22, 2025 $0.23; Dec 22, 2025 $0.42; Mar 23, 2026 $0.08; Jun 22, 2026 $0.81; Sep 21, 2026 $0.02. Use the arrow keys to read each point.2017201820192020202120222023202420252026YTD
Ex-datePay dateAmount per share
Sep 21, 2026Sep 25, 2026$0.02
Jun 22, 2026Jun 26, 2026$0.81
Mar 23, 2026Mar 27, 2026$0.08
Dec 22, 2025Dec 26, 2025$0.42
Sep 22, 2025Sep 26, 2025$0.23
Jun 23, 2025Jun 27, 2025$0.13
Mar 24, 2025Mar 28, 2025$0.03
Jun 24, 2024Jun 28, 2024$0.0082
Mar 18, 2024Mar 22, 2024$0.02
Jun 20, 2023Jun 23, 2023$0.01
Mar 23, 2020Mar 31, 2020$0.03
Sep 24, 2018Sep 28, 2018$0.0021

See all 22 payments⁠

$10,000 in PBE 10 years ago paid $600 in dividends.⁠

PBE Risk

Risk pillarA76 out of 100Rank 1 of 17 in Biotech & Genomics
How much the fund’s monthly returns vary, scaled to a year.
16.2%
Annualised · 36 months to Oct 2026
How it’s calculated: standard deviation

The sample standard deviation of monthly total returns, multiplied by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.

Return above 3-month US Treasury bills per unit of volatility.
1.19
vs 3-month T-bills · to Oct 2026
How it’s calculated: Sharpe ratio

Subtract each month’s Treasury-bill return from the fund’s monthly total return.

Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.

Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.

The largest fall from a peak to the low that followed.
−32.6%
Trough Jun 2022
How it’s calculated: maximum drawdown

The largest percentage decline from an earlier peak, using total returns with reinvested distributions.

Uses up to five years through the last close, with at least 12 months required.

How strongly the fund’s returns move with its asset-class index.
0.79
vs its asset-class index
How it’s calculated: beta

The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.

FMP measures it over up to five years of monthly returns.

PBE Cost

Compare PBE and IBBQ

Overpaying vs IBBQ, cheapest in Biotech & Genomics

$7,683

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • PBE 0.59%

    $11,635

  • IBBQ 0.19% Cheapest

    $3,952

$10,000
30 years

Cost over time

  • PBE 0.59%
  • IBBQ 0.19%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2.5K$5K$7.5K$10K$12.5K051015202530PBE $11,635IBBQ $3,952

Year by year

YearPBEIBBQOverpaying
10$1,058$347$711
20$4,051$1,351$2,700
30$11,635$3,952$7,683

Other funds in Biotech & Genomics

See others